Literature DB >> 17234754

IFN-alpha-stimulated genes and Epstein-Barr virus gene expression distinguish WHO type II and III nasopharyngeal carcinomas.

D Michiel Pegtel1, Aravind Subramanian, David Meritt, Ching-Hwa Tsai, Tzung-Shiahn Sheen, Todd R Golub, David A Thorley-Lawson.   

Abstract

Nonkeratinizing nasopharyngeal carcinoma (NPC) is 100% associated with Epstein-Barr Virus (EBV) and divided into two subtypes (WHO types II and III) based on histology. We tested whether these subtypes can be distinguished at the molecular genetic level using an algorithm that analyzes sets of related genes (gene set enrichment analysis). We found that a class of IFN-stimulated genes (ISG), frequently associated with the antiviral response, was significantly activated in type III versus type II NPC. Consistent with this, replication of the endogenous EBV was suppressed in type III. A strong association was also seen with a subset of ISGs previously identified in systemic lupus erythematosus, another disease in which 'normal' EBV biology is deregulated, suggesting that this pattern of ISG expression may be linked to the increased EBV activity in both diseases. In contrast, unsupervised hierarchical clustering of the complete expression profiles failed to distinguish the two subsets. These results suggest that type II and III NPC have not originated from obviously distinct epithelial precursors; rather, the histologic differences may be a consequence of a differential antiviral response, involving IFNs, to chronic EBV infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17234754     DOI: 10.1158/0008-5472.CAN-06-1882

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Nasopharyngeal carcinoma: our experience.

Authors:  Carla d'Espiney Amaro; Pedro Montalvão; Pedro Henriques; Miguel Magalhães; João Olias
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-10-02       Impact factor: 2.503

2.  BST2 confers cisplatin resistance via NF-κB signaling in nasopharyngeal cancer.

Authors:  Chun-Mei Kuang; Xiang Fu; Yi-Jun Hua; Wen-di Shuai; Zhi-Hua Ye; Yingchang Li; Qi-Hua Peng; Yi-Zhuo Li; Shuai Chen; Chao-Nan Qian; Wenlin Huang; Ran-Yi Liu
Journal:  Cell Death Dis       Date:  2017-06-15       Impact factor: 8.469

3.  Vesicle-bound EBV-BART13-3p miRNA in circulation distinguishes nasopharyngeal from other head and neck cancer and asymptomatic EBV-infections.

Authors:  Octavia Ramayanti; Sandra A W M Verkuijlen; Putri Novianti; Chantal Scheepbouwer; Branislav Misovic; Danijela Koppers-Lalic; Jan van Weering; Lisa Beckers; Marlinda Adham; Debora Martorelli; Jaap M Middeldorp; Dirk Michiel Pegtel
Journal:  Int J Cancer       Date:  2018-12-06       Impact factor: 7.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.